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Abstract
Background: The aim of this work is to evaluate efficacy and tolerability of preservative containing 0.0015%
tafluprost and preservative-free 0.0015% tafluprost using a prospective crossover study.
Methods: Primary open angle glaucoma (POAG) and normotensive glaucoma (NTG) patients were randomized
enrolled. Group 1 (“NPT to PT”) patients used preservative-free 0.0015% tafluprost (NPT) for 6 months and then
changed to preservative containing 0.0015% tafluprost(PT) for 6 months. Group 2 (“PT to NPT”) patients used
preservative containing 0.0015% tafluprost for 6 months and changed to preservative-free 0.0015% tafluprost for
6 months. At 1, 3, 6, 7, 9, and 12 months, we measured intraocular pressure for efficacy and graded corneal erosion,
tear break-up time (TBUT), and subjective discomfort.
Results: A total of 20 patients and 20 eyes were enrolled. In Group 1 and 2, intraocular pressure was well
controlled to approximately 14 mmHg (9.38–18.46% decrease). Generally, subjective satisfaction was improved after
changing from PT to NPT (p = 0.03) and TBUT using PT was numerically inferior to that using NPT (p = 0.06) but not
when changing from NPT to PT.
Conclusion: Both preservative containing and preservative-free 0.0015% tafluprost reduced intraocular pressure
significantly. In addition, changing medication from PT to NPT might improve subjective satisfaction and tear break
up time.
Trial registration: The trial registration number is NCT 03104621 (Apr/1/2017). Retrospectively registered.
Keywords: Tafluprost, Preservative, Efficacy, Tolerability
Background
Glaucoma is the leading cause of irreversible visual loss
accompanying optic neuropathy and specific visual field
deficits. Many factors contribute to the development of
glaucoma; however, intraocular pressure (IOP) is the
most important factor. The control of IOP is currently
the only management option for glaucoma [1–3].
Many anti-glaucoma drugs are delivered via eyedrops,
but the effects of lowering IOP vary from 10 to 30% [1–3].
Glaucoma patients typically use anti-glaucoma eyedrops
for a long time. Not only the effect of anti-glaucoma eye
drops, but also their tolerability are very important to
patients.
Among anti-glaucoma eyedrops, prostaglandin ana-
logues are one of the most effective drugs for lowering
IOP. The prostaglandin analogue acts by increasing
aqueous drainage through the non-conventional uveoscl-
eral pathway [1]. The IOP lowering effect of prostaglan-
din analogues is approximately 27–35%. Prostaglandin
analogues have feweradverse effects compared to other
IOP lowering drugs [2, 4]. In this study, we will discuss
Tafluprost.
In the process of making anti-glaucoma drugs, pre-
servatives are used widely for preventing denaturation
of the eyedrops and preserving the drug for a long time.
Benzalkonium chloride (BAK) is the most used preser-
vative and is excellent for safety and stability of drug.
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However, it causes dry eye, corneal oedema, corneal ero-
sion, and corneal toxicities, thus lowering the long-term
tolerability for patients [5–7]. A critical component when
managing glaucoma patients is ensuring compliance.
However, adverse effects decrease the compliance of regu-
lar eye drop application in glaucoma patients.
Once the toxicities of BAK were reported, efforts began
to reduce preservatives while preventing denaturation of
the drugs. Substitutions for BAK have been found [8–10]
and preservative-free disposable packs for one-timeuse
have been developed [11].
The adverse effects of prostaglandins are conjunctival
injection and pigmentation of both the iris and periocular
area [2]. BAK also has toxicities on cornea erosion and
dry eye [5–7]. In this study, we investigated the effect of
0.0015% Tafluprost and the tolerability between BAK con-
taining product (Taflotan®) and non-preservative dispos-
able pack product (Taflotan-S®). Many ophthalmologists
want to prescribe prostaglandin analogues for effective
IOP reduction and non-preservative medications for
lowering adverse effects. In those aspects, Taflotan-S® is
currently the only glaucoma medication that is com-
mercially available as a non-preservative prostaglandin
analogue.
Methods
This prospective, crossover study protocol followed the
tenets of the Declaration of Helsinki and was approved
from the Institutional Review Board of Gangnam Sever-
ance Hospital, Yonsei University College of Medicine.
All subjects were provided informed consent. Between
Jan 2013 and Sep 2015, patients from the Gangnam
Severance Hospital eye center (Seoul, South Korea)
were recruited. Study subjects were the initially diag-
nosed glaucoma patients. We decided sample size by
program (G power®, copyright by Heinrich-Heine-
Universitat Dusseldorf ), which provides appropriate
sample size calculating. With one tailed matched pairs
Wilcoxon signed-rank test, we could gain twenty sub-
jects of total sample sizes. Effect size was 80% and α
error was 0.05. We constructed cross over study, one
group was consisted 10 subjects. This prospective, com-
parative, crossover study recruited patients into two
groups. Group 1 is “NPT to PT”. For the first 6 months,
the subjects of group 1 used non-preservative dispos-
able 0.0015% tafluprost product (Taflotan-S®, Santen
Pharmaceutical Co. Ltd, Osaka, Japan) and then chan-
ged to 0.001% Benzalkonium chloride (BAK), 0.0015%
tafluprost product (Taflotan®, Santen Pharmaceutical
Co. Ltd, Osaka, Japan) for 6 months. Group 2 is “PT to
NPT”. These subjects used Taflotan® for the first
6 months and then changed to Taflotan-S® for 6 months.
Subjects used one drop tafluprost (whether preserva-
tives or preservative free) once a day at night. Subjects
were randomly arranged into group 1 or group 2. Sub-
jects were randomized by simple randomization. Before
subjects were enrolled, the sequence of enrollment was
formed, whether preservative product use first or not
(group 1or 2). For example, we had the sequence of
enrollment by flipping coin; (group) 1-2-1-1-2-1-2-2-2-
1-2-1-2-1-2-1-2-2-1-1. If one patient decided to be en-
rolled at outpatient clinic on fourth subject, (s)he was
enrolled to group 1. During the study, subjects stopped
tafluprost if severe adverse effects appeared.
Primary open angle glaucoma and normotensive glau-
coma patients who came to the outpatient clinic for
regular glaucoma check-ups were enrolled. Glaucoma
was defined as the patients who had open angle con-
firmed by gonioscopy, optic nerve cupping (a vertical
cup-disc ratio of >0.6) and or notching of the neuroret-
inal rim and or retinal nerve fiber defects characteristics
of glaucoma, and visual field defect (i.e., a glaucoma
hemi-filed test result outside normal limits, a pattern
standard deviation probability of <5%, or a cluster of
three or more non-edge points in location typical of
glaucoma, all of which were depressed on a pattern devi-
ation plot at a P level of <5%, and at least one of which
was depressed at a P level of <1% on two consecutive
visual field tests). Normal tension glaucoma included
criteria: repeated measurements of untreated IOP values
of < 21 mmHg. Primary open angle glaucoma included
criteria: repeated measurements of untreated IOP values
of ≥ 22 mmHg. Phakic and pseudophakic eyes were en-
rolled but aphakic eyes were excluded. Also, eyes that
had been taken vitrectomy, trabeculectomy, or through
other surgery influencing IOP were excluded. If both eye
were glaucoma, the eye which had more severe visual
field defect and higher IOP was enrolled. At baseline, we
performed visual acuity, IOP, visual field test (SITA-
Standard 30–2 programme; HFA II-750i, Carl Zeiss
Meditec®, CA, USA), slit lamp examination, and admin-
istered a questionnaire.
Patients were equally randomized in double blind man-
ner to preservative or non-preservative tafluprost. The 20
enrolled patients did not have washout periods between
the two products (Taflotan® and Taflotan-S®). Investigators,
patients and other study participants were blinded to
treatment assignment throughout the study. Evaluator of
IOP was also masked to treatment assignment. We
checked corneal erosion status, tear break up time, Schir-
mer test under topical anaesthesia (5% Proparacaine HCl,
Alcaine®, Alcon Laboratories Inc., TX, USA), and adminis-
tered a questionnaire for subjective discomfort after 1, 3,
and 6 months using one drug. After changing to the other
product, similar follow up tests occurred at 1, 3, and
6 months. IOP was checked by Goldmann applanation to-
nometry in the morning during the hours of clinic oper-
ation (9:00 am to 12:00 pm). We modified Ocular surface
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disease Index (OSDI); questionnaire questions included
subjective discomfort such as stinging sensation, itch-
ing, dryness, foreign body sensation, and conjunctival
injection. The subjective discomfort scaleincluded “0”
(no discomfort), “1” (mild discomfort), and “2” (severe
discomfort) [3]. The scores of each question were
summed. Corneal erosion scales were scored according
to the area of erosion. Little to no erosion was “0”,
erosion on 1/3 of the area of the entire cornea was “1”,
erosion on 2/3 of the area of the entire cornea was “2”,
and erosion on the entire cornea was “3” (Fig. 1) [7].
For tear secretion, schirmer test paper was placed into
the conjunctival sac at the point of 1/3 from lateral
canthus under topical anaesthesia (5% Proparacaine
HCl, Alcaine®, Alcon Laboratories Inc., TX, USA). After
5 min, we checked the wet height with tear (mm). Tear
breakup time was checked by slit lamp exam under cor-
neal fluorescein dye. We asked patients not to blink,
and the time was counted until tear film was torn apart
(seconds).
All data were analysed by SPSS® (IBM®, SPSS Statistics
ver. 20) using student t-test, Chi square test and Wil-
coxon signed rank test. In case of multiple comparisons,
t-test and Chi-square tests with Bonferroni correction
were used.
Results
Subject characteristics
Among the 20 subjects, 10 were assigned to each group.
The mean age was 55.26 ± 14.22 years. The mean age of
group 1 was 55.90 ± 15.98 years and group 2 was 54.55
± 12.90 years. Five males and five females were in each
group. Eleven subjects had systemic disease (two had
diabetes mellitus and nine had hypertension). Three sub-
jects smoked (Table 1). Two patients were primary open
angle glaucoma patients and 18 were normotensive glau-
coma patients. The mean visual acuity (LogMAR) was
0.116 in group 1 and 0.096 in group 2. The mean devi-
ation (MD) of the Humphrey test was −7.50 ± 6.43 dB
and the visual field index (VFI) was 78.31 ± 22.77%. MD
and VFI of group 1 were −8.56 ± 7.66 dB and 73.20 ±
26.35%. MD and VFI of group 2 were −6.32 ± 4.90 dB
and 84.00 ± 17.79% (Table 2).
Intraocular pressure reduction
IOP was analysed for the 20 patients. Both products
contained 0.0015% tafluprost, but differed in the BAK
content. To analyse the IOP reduction effect of taflu-
prost, IOP was checked before and after using tafluprost
for 1, 3, 6, 7, 9, and 12 months. The mean IOP before
using tafluprost decreased from 16.84 ± 2.75 mmHg to
14.85 ± 3.05 mmHg (11.81%) after 12 months of use.
The means of IOP at 1, 3, 6, 7, 9, and 12 months were
significantly lower compared to the IOP before using
tafluprost (p < 0.01) (Table 2, Fig. 2).
Subjective discomfort
Subjective discomfort (summed score of stinging sensa-
tion, itching, dryness, foreign body sensation, and con-
junctival injection) was significantly improved in group
2 (PT to NPT). Before exchanging products, the scores
of subjective symptoms was 1.14 ± 0.69 (points). After
Fig. 1 (a) Corneal erosion grade 0; Little to no erosion (b) Corneal erosion grade 1; erosion on lower than 1/3 of the area of the entire cornea (c)
Corneal erosion grade 2; erosion on 1/3 to 2/3 of the area of the entire cornea (d) Corneal erosion grade 3; erosion on the nearlyentire cornea
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6 months of NPT (at 12 months), the scores of subject-
ive symptoms were significantly improved to 0.87 ± 1.72
(points) (p = 0.03) (Fig. 3, Table 3).
In group 1 (NPT to PT) after 1 month using NPT, sub-
jective symptoms were significantly worsened. At baseline,
the score of subjective symptoms was 0.70 ± 0.67 (points)
and after 1 month using NPT, the score increased to 1.87
± 1.24 (points) (p = 0.02). This may be due to conjunctival
redness, which is the most common adverse effect of
prostaglandin analogues. After 6 months, the subjective
symptoms score recovered to 0.80 ± 1.39 (points) (Fig. 3,
Table 3). After exchanging medication to PT, subjective
symptoms did not severely worsen.
Corneal erosion grade/Schirmer test
In group 1, using NPT and changing to PT increased
corneal erosion grade, in other words, worsened corneal
erosion. Before medication, the score of corneal erosion
was 0.30 ± 0.48 (points) but after 12 months, the score
increased to 0.60 ± 0.54 (points). PT might make corneal
erosion more severe, but it was not statistically signifi-
cant. In group 2, using NPT increased corneal erosion
from 0.14 ± 0.37 to 0.80 ± 0.83, but it was not statistically
significant (Fig. 4, Table 3).
Throughout the study, the Schirmer test results were
not changed significantly by changing medication (Fig. 5,
Table 3).
Tear break up time (TBUT)
In group 1 (NPT to PT) after 1 month of using NPT,
tear breakup time (TBUT) was significantly worsened.
At baseline, the TBUT score was 5.80 ± 2.39 (sec), but
after 1 month using NPT, the TBUT score decreased to
3.25 ± 1.28 (sec) (p = 0.03). However, after 6 months, the
scores recovered to the baseline score, 5.00 ± 1.88 (sec)
(Fig. 6, Table 3). PT made tear break up time worse. In
group 1 before exchanging to PT (at 6 months), tear
break up time was 5.00 ± 1.88 (sec). After using PT (at
12 months), tear break up time was decreased to 3.60 ±
2.07 (sec) (p = 0.06) (Fig. 6, Table 3).
Discussion
0.0015% Tafluprost is effective in lowering intraocular
pressure (IOP) in many studies and is comparable to
other prostaglandin analogues (Latanoprost, Travoprost,
Bimatoprost). According to Kuwayama et al., after apply-
ing Tafluprost for 2 months, IOPs were reduced by 4.3 ±
5.2 mmHg in primary open angle glaucoma patients, 2.4
± 2.5 mmHg in normotensive glaucoma patients, and
5.6 ± 7.1 mmHg in angle closure glaucoma patients [1].
Hwang et al. showed that 0.0015% Tafluprost reduced
IOP of primary open angle glaucoma patients to about
4.6 mmHg (23.0%) in 1 month, 5.1 mmHg (25.5%) in
3 months, and 4.9 mmHg (24.5%) in 6 months [11].
Similarly, our study found that 0.0015% Tafluprost re-
duced IOP significantly and maintained reduced IOP for
one year.
Subjective discomfort was improved after changing from
PT to NPT (p = 0.03). However, other studies did not say
that NPT was superior to PT in subjective discomfort.
The product of Tafluprost (Taflotan®) contains a relatively
low concentration (0.001%) of BAK compared to other
Table 1 Patients demographics
Total (n = 20) Group 1 (n = 10) Group 2 (n = 10) p
Age (years) 55.26 ± 14.22a 55.90 ± 15.98a 54.55 ± 12.90a 0.73
Sex (M:F) 10:10 5:5 5:5 1.00†
Systemic disease (DM) 2 1 1 1.00†
Systemic disease (Hypertension) 9 5 4 0.52†
Smoking history 3 2 1 0.06†
Laterality (R:L) 8:12 5:5 3:7 0.20†
DM diabetes mellitus
aaverage ± standard deviation; p, p-values; †chi-square test
Table 2 Ophthalmic characteristics
Total (n = 20) Group 1 (n = 10) Group 2 (n = 10) p
POAG:NTG 2:18 1:9 1:9 1.00†
Visual acuity (LogMAR) 0.106 0.116 0.096 0.98
IOP (mmHg) 16.84 ± 2.75a 16.70 ± 3.02a 17.00 ± 2.59a 0.74
MD (dB) −7.50 ± 6.43a −8.56 ± 7.66a −6.32 ± 4.90a 0.32
VFI (%) 78.31 ± 22.77a 73.20 ± 26.35a 84.00 ± 17.79a 0.31
POAG primary open angle glaucoma, NTG normotensive glaucoma, IOP intraocular pressure, MD mean deviation, VFI visual field index
aaverage ± standard deviation; p, p-values; †chi-square test
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prostaglandin analogue products (Xalatan® from Pfizer:
0.02% BAK; Lumigan® from Allergan: 0.005% BAK; Trava-
tan Z® from Alcon: sofzia). Because of the relatively low
concentration of BAK, Taflotan® is thought toinduce fewer
ocular surface problems and patient discomfort. In this
study, the differences of subject discomfort were not def-
inite after exchanging the products (PT to NPT or NPT
to PT).
Suzuki et al. evaluated corneal toxicities of anti-
glaucoma eye drops in severe superficial punctate keratop-
athy. Corneal status and tear break up time were checked
for 12 weeks using 0.0015% Tafluprost (0.001% BAK),
0.005% Latanoprost (0.02% BAK), 0.004% TravoprostZ
(sofzia), and 0.03% Bimatoprost (0.005% BAK). This study
reported that BAC concentrations under 0.003% cau-
seda few corneal toxicities, but the ones above 0.005%
BAK aggravated corneal erosion and shortened tear
break up time [7]. Pinheiro et al. found that 0.02%
BAK aggravated corneal abrasions from 14.65 mm2 to
66.57 mm2 to87.26 mm2 in area. Iatrogenic corneal
abrasions were healed completely and recovered cor-
neal stroma (Descemet’s membrane) structure in the
Tafuprost use group, but delayed corneal healing
markedly in the Latanoprost use group [5]. Fogagnolo
et al. studied the confocal microscopic findings of
non-preservative tafluprost and latanoprost in glau-
coma patients for 1 year. Clinical effects (IOP reduc-
tion) was similar in both group, 3.6–4.2 mmHg.
However, corneal nerve branching patterns were
significantly different between both groups. None of
the patients without beading at baseline developed
beading at the end of the study in non-preservative
tafluprost group, whereas this occurred in 6/8 (75%)
patients treated with latanoprost [12].
In summary, a low concentration of BAK (under
0.003%) causes few corneal toxicities and Tafluprost has
less toxicities compared to other prostaglandin analogues.
Thus, 0.001% BAK containing Tafluprost may have little
chance to cause corneal toxicities. However, because the
non-preservative product improved subjective satisfaction,
recommending non-preservative product to glaucoma pa-
tients is beneficial for maintaining anti-glaucoma eye drop
compliance for a long period.
Fig. 2 Intraocular pressure (IOP) before and after using 0.0015% tafluprost. Indicated numbers are the means of intraocular pressure before
using tafluprost and after 1, 3, 6, 7, 9, and 12 months of use. 1 month after using tafluprost, IOP was well maintained for 12 month. (* : p < 0.001,
# : p > 0.05)
Fig. 3 Subjective discomfort in Group 1 (NPT→ PT) and Group 2
(PT→ NPT). Before exchanging product (6 m) and after 6 month
(12 m), the reduction of score was significant in Group 2. (p = 0.03)
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In group 1, even with the non-preservative product,
subjective discomfort increased significantly after 1 month.
We think that conjunctival injection mostly influenced
this situation. The most common adverse effect of prosta-
glandin analogues is conjunctival injection. Conjunctival
injections are most severe during the first 2 weeks, and
gradually subside after that. In the same manner, patients
in our study were relieved from conjunctival injection
after 3 months.
Our study population had many normotensive glau-
coma (NTG) patients, one primary open angle glaucoma
(IOP over 21 mmHg), and nine normotensive glaucoma
(IOP under 21 mmHg) patients. In NTG patients, IOP re-
duction following prostaglandin analogue use commonly
ranged from 15.3% to 22.6%, even though there were non-
responders to prostaglandin analogues (0–15%) [13, 14]. It
is thought that the results in this study (9.38–18.46% IOP
reduction) showed ordinary efficacy.
This study had some limitations. First, the number of
enrolled subjects for this study was small. Second, this
study was designed for only one year. To evaluate the
effect and tolerability of the drug, more subjects and a
longer follow-up period are needed. Third, we did not
have washout periods. Commonly, crossover studies for
drugs have clearance periods for the initial drug to be
cleared from the system before starting the second drug.
However, maintaining anti-glaucoma drug treatment is
important for glaucoma patients, thus making a long
wash out period unfeasible.
This study is the first prospective designed crossover
study for evaluating efficacy and tolerability of 0.0015%
Tafluprost. A crossover study is a randomized, controlled
longitudinal study in which subjects receive a sequence of
different treatment. Nearly all crossover study designs
have balance, which means that all subjects should receive
the same number of treatments and that all subjects par-
ticipate for the same number of periods. A crossover study
has advantages in the reduced confounding covariates.
Each crossover patient serves as his or her own control, so
crossover study design can reduce confounding covariates.
We performed our study for two different drugs in one
subject; thereby many variables could be controlled.
Crossover studies do have some limitations. First is the
order effect. Treatment order may affect the outcome. An
example might be a drug with many adverse effects given
first, making patients taking a second, less harmful medi-
cine more sensitive to any adverse effect. Second is the
learning effect. Patients learn how to better apply the drug
over time. Therefore, the second drug may have been
more carefully applied than the first.
Conclusion
0.0015% tafluprost reduced intraocular pressure signifi-
cantly, whether it contained preservative or not. In addition,
changing from preservative containing 0.0015% Tafluprost
to preservative-free 0.0015% Tafluprost improved subjective
Fig. 4 Corneal erosion grade in Group 1 (NPT→ PT) and Group 2
(PT→ NPT). Corneal erosion was increased using PT, but it was not
statistically significant
Fig. 5 The results of Schirmer test in Group 1 (NPT→ PT) and Group 2
(PT→NPT)
Fig. 6 The results of tear break up time (TBUT) in Group 1 (NPT→ PT)
and Group 2 (PT→ NPT). Comparison between baseline TBUT and
after 12 months of treatment showed a slightly decreased TBUT in
Group 1 (NPT→ PT). (p = 0.06)
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satisfaction and tear break up time. Preservative free Taflu-
prost may give glaucoma patients not only treatment effect
but also improve satisfaction.
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